[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100516281":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":55,"collaborators":26,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":26,"enrollmentInfo":70,"targetDuration":26,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":26,"overallStatus":43,"whyStopped":26,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Vanderbilt University Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Anticholinergic Challenge","EXPERIMENTAL","All participants will receive oral mecamylamine for 1 day",[13],"Drug: Mecamylamine Challenge",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Challenge","PLACEBO_COMPARATOR","All participants will receive oral placebo for 1 day",[19],"Other: Placebo Comparator Challenge",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Mecamylamine Challenge","Mecamylamine 20 mg oral pill administered once",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo Comparator Challenge","Matching placebo oral pill administered once",[15],[32],{"name":33,"affiliation":5,"role":34},"Paul Newhouse, MD","STUDY_DIRECTOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Kimberly Albert, PhD","CONTACT","6159364559","kimberly.albert@vumc.org",[42],{"facility":5,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":26},"RECRUITING","Nashville","Tennessee","37212","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-86.78444,36.16589,{"lat":53,"lon":52},{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Kimberly Albert","Research Assitant Professor, Psychiatry","100516281","early-phase-1-attentional-mechanisms-in-scd-100516281",false,"NCT06002477","Attentional Mechanisms in SCD","Attentional Mechanisms of Cognitive Compensation in Subjective Cognitive Decline","AMoCC-SCD","Inclusion Criteria:\n\n1. age ≥ 55\n2. Montreal Cognitive Assessment (MoCA) \\> 25 AND Global Deterioration Scale (GDS) rating \\\u003C 3\n3. Non-smokers\n\nExclusion Criteria:\n\n1. medical contraindications to the drug challenge\n2. primary neurological disorder (such as stroke, epilepsy, etc.)",true,"ALL","55 Years",{"count":71,"type":72},80,"ESTIMATED","INTERVENTIONAL",[75],"EARLY_PHASE1","This study will use an anticholinergic pharmacological probe to examine attention network function in SCD using EEG. The overall hypothesis is that in older adults with SCD, normal cognitive performance is maintained by compensatory attention network activity, supported by enhanced cholinergic function. The investigators anticipate that SCD will be associated with greater compensatory attention network activity and that disrupting this compensatory process through anticholinergic challenge will result in a greater negative effect on attentional performance (Attention Network Test, ANT) and attention network functioning (EEG) in older adults with greater subjective cognitive concern.",[78],"Subjective Cognitive Decline","2026-06-02",{"date":81,"type":82},"2026-06-04","ACTUAL",{"date":84,"type":82},"2025-06-06",{"date":86,"type":72},"2028-06-30",{"name":5,"class":6},1]